News Sentiment

RNAC sentiment intelligence

Cartesian Therapeutics Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 51 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 9.46 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 43

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

-10.7% over one week, -0.5% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

Enterprise value to EBITDA forward of Cartesian Therapeutics, Inc. – NASDAQ:RNAC

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction -10.7% Price reacting lower
Trend fit Trend active -0.5% over four weeks
Fair value -44.1% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 11
Neutral 36
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 43
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
TradingView 9
Market source 7
Stock Titan 5
simplywall.st 4
24/7 Wall St. 3
TradingKey 3
GlobeNewswire 3
MSN 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 13
Analyst action 3
Deals and strategy 3
Balance sheet 3
Macro sensitivity 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 51
TradingView Direct company coverage

Enterprise value to EBITDA forward of Cartesian Therapeutics, Inc. – NASDAQ:RNAC

This article displays financial data for Cartesian Therapeutics, Inc. (NASDAQ: RNAC), focusing on its enterprise value to EBITDA forward metric. The content appears to be a financial data snippet from TradingView, indicating no current trades and providing links to various financ

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 22:43
Source
TradingView
MSN Direct company coverage

Cartesian Therapeutics Inc (RNAC)

This article provides key financial data for Cartesian Therapeutics Inc (RNAC), a biotechnology and medical research company listed on the Nasdaq Stock Market. It summarizes its stock price, daily and 52-week ranges, market capitalization, outstanding shares, and earnings per sha

Tone
Negative 39/100
Event
Earnings
Published
12 Jul 2026 22:40
Source
MSN
24/7 Wall St. Direct company coverage

Cartesian Therapeutics : RNAC

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 19:59
Source
24/7 Wall St.
24/7 Wall St. Direct company coverage

Cartesian Therapeutics Inc. : RNAC

This article provides details on Cartesian Therapeutics Inc. (RNAC), a clinical-stage biopharmaceutical company focusing on nanoparticle immunomodulatory drugs. It lists the company's stock data, including its NASDAQ exchange, USD currency, and its classification within the healt

Tone
Neutral 50/100
Event
Macro sensitivity
Published
10 Jul 2026 20:41
Source
24/7 Wall St.
Barchart.com Direct company coverage

Emerging Therapies Transforming the Myasthenia Gravis Market by DelveInsight | Sanofi, Cartesian Therapeutics, Takeda, UCB Biopharma, Roche, Janssen R&D, Immunovant Sciences GmbH, Argenx-Halozyme

The Myasthenia Gravis market is projected to grow significantly from approximately USD 6 billion in 2025 to nearly USD 16 billion by 2036, driven by new therapies and increased awareness. Recent FDA approvals for treatments like Vyvgart and UPLIZNA have expanded options for patie

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 08:40
Source
Barchart.com
MSN Direct company coverage

Wedbush Initiates Coverage of Cartesian Therapeutics (RNAC) with Outperform Recommendation

Wedbush has initiated coverage of Cartesian Therapeutics (RNAC) with an Outperform recommendation. This indicates a positive outlook from the analyst firm regarding the company's stock performance. Investors will likely watch for further developments and market reactions to this

Tone
Positive 75/100
Event
Analyst action
Published
04 Jul 2026 20:09
Source
MSN
The Manila Times Direct company coverage

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics, Inc. has granted inducement awards to eight new employees, issuing options to purchase a total of 238,700 shares of common stock at an exercise price of $10.18. These options, vesting over four years, were granted on July 1, 2026, under the Company’s Amend

Tone
Positive 64/100
Event
Market update
Published
03 Jul 2026 06:38
Source
The Manila Times
Stock Titan Direct company coverage

Cartesian offers 8 new hires stock options worth 238,700 shares

Cartesian Therapeutics (NASDAQ: RNAC) granted inducement stock options for 238,700 common shares to eight new employees, effective July 1, 2026. The options have an exercise price of $10.18 and will vest 25% on July 1, 2027, with the remainder vesting monthly until July 1, 2030.

Tone
Positive 63/100
Event
Market update
Published
02 Jul 2026 10:41
Source
Stock Titan
Finviz Direct company coverage

RNAC - Cartesian Therapeutics Inc Latest SEC Filings

This article provides the latest SEC filing information for Cartesian Therapeutics Inc. (RNAC), including its last closing price, financial overview, stock performance metrics, insider and institutional ownership, and profitability ratios. It details various financial statistics

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 05:10
Source
Finviz
TradingView Direct company coverage

Enterprise value to EBIT forward of Cartesian Therapeutics, Inc. – NASDAQ:RNAC

This article provides the enterprise value to EBIT forward for Cartesian Therapeutics, Inc. (NASDAQ: RNAC). It appears to be a financial data snippet from TradingView, focusing on key financial metrics for the biotechnology company. The content primarily lists navigation and site

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 06:40
Source
TradingView
TradingView Direct company coverage

Price to book forward of Cartesian Therapeutics, Inc. – GETTEX:1S70

The article provides financial information for Cartesian Therapeutics, Inc. (GETTEX:1S70), specifically focusing on its "Price to book forward" metric. It appears to be a financial data page from TradingView, showing that the market is closed with no trades.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 15:10
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Cartesian Therapeutics, Inc. – NASDAQ:RNAC

This article provides financial information for Cartesian Therapeutics, Inc. (NASDAQ: RNAC) focusing on its price-to-earnings forward metric. It appears to be a stub or an incomplete data listing from a financial platform like TradingView, with placeholders for specific values. T

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 13:41
Source
TradingView
TradingView Direct company coverage

Cartesian Therapeutics, Inc. Actuals & Estimates (NASDAQ:RNAC)

This article provides an overview of Cartesian Therapeutics, Inc. (NASDAQ: RNAC) stock, including its current price, historical highs and lows, market capitalization, and analyst forecasts. It details financial actuals and estimates for income, balance, and cash flow statements,

Tone
Neutral 50/100
Event
Analyst action
Published
26 Jun 2026 08:09
Source
TradingView
TradingView Direct company coverage

Cartesian Therapeutics, Inc. Actuals & Estimates (BOATS:RNAC)

This article provides an overview of Cartesian Therapeutics, Inc. (RNAC) stock, including its financial actuals and estimates as traded on BOATS exchange. It covers analyst forecasts, historical price data, upcoming earnings reports, and key financial metrics like revenue, net in

Tone
Negative 40/100
Event
Earnings
Published
26 Jun 2026 06:41
Source
TradingView
TradingView Direct company coverage

Price to sales forward of Cartesian Therapeutics, Inc. – GETTEX:1S70

This page provides financial information for Cartesian Therapeutics, Inc. under the ticker GETTEX:1S70, specifically focusing on its price-to-sales forward metric. The data is explicitly noted as "Made by humans" and the market status is closed with no trades.

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 22:40
Source
TradingView
TradingKey Direct company coverage

Cartesian Therapeutics Inc (RNAC) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Cartesian Therapeutics Inc (RNAC), detailing its current price momentum, support and resistance levels, and indicator readings. It highlights that the stock is trading between resistance at $12.06 and support at $7.03, suitable for ra

Tone
Positive 64/100
Event
Market update
Published
24 Jun 2026 10:12
Source
TradingKey
TradingView Direct company coverage

RNAC Forecast — Price Target — Prediction for 2027

This article provides a stock forecast for Cartesian Therapeutics, Inc. (RNAC) including analyst price targets, current stock performance, and historical price data. It also details the company's financials, future earnings expectations, and market capitalization, offering insigh

Tone
Neutral 50/100
Event
Analyst action
Published
24 Jun 2026 08:10
Source
TradingView
Simply Wall Street Direct company coverage

Cartesian Therapeutics (Nasdaq:RNAC) - Stock Analysis

Cartesian Therapeutics (Nasdaq:RNAC) is a clinical-stage biotechnology company developing mRNA cell therapies for autoimmune diseases. The stock is currently trading significantly below its estimated fair value, but faces risks including negative shareholder equity, volatile shar

Tone
Positive 67/100
Event
Market update
Published
22 Jun 2026 02:10
Source
Simply Wall Street
The Globe and Mail Direct company coverage

Cartesian Therapeutics Shareholders Back Directors and Governance Measures

Cartesian Therapeutics shareholders demonstrated strong support for the company's leadership and governance, electing three Class I directors and approving executive compensation. They also ratified Ernst & Young LLP as their independent public accounting firm for 2026, indicatin

Tone
Negative 40/100
Event
Market update
Published
19 Jun 2026 00:39
Source
The Globe and Mail
Stock Titan Direct company coverage

Shareholders of Cartesian Therapeutics (NASDAQ: RNAC) back board, pay and auditor

Cartesian Therapeutics (NASDAQ: RNAC) shareholders held their 2026 Annual Meeting, with an 82.42% turnout. They elected three Class I directors to serve until the 2029 Annual Meeting, approved executive compensation on an advisory basis, and ratified Ernst & Young LLP as their in

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 20:10
Source
Stock Titan
TradingKey Direct company coverage

Cartesian Therapeutics Inc (RNAC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey reports on Cartesian Therapeutics Inc (RNAC)'s stock performance, showing a 5% gain. However, it notes that relevant data regarding the company's revenue breakdown by business segments and regions has not yet been disclosed. The page primarily serves

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 09:10
Source
TradingKey
TradingKey Direct company coverage

Cartesian Therapeutics Inc (RNAC) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Cartesian Therapeutics Inc (RNAC), detailing its current earnings forecast score, analyst ratings, and price targets. It highlights that the company's expected revenue for the next quarter is $134.75K and the average analyst price ta

Tone
Positive 63/100
Event
Earnings
Published
16 Jun 2026 23:40
Source
TradingKey
GuruFocus Direct company coverage

Cartesian Therapeutics Inc PE Ratio (TTM) & PE Ratio (TTM) Charts - RNAC

This article from GuruFocus.com provides a detailed financial overview of Cartesian Therapeutics Inc (RNAC), focusing on its Price-to-Earnings (PE) Ratio (TTM). It highlights that the company is currently operating at a loss, thus its TTM PE ratio is listed as "At Loss." The arti

Tone
Neutral 50/100
Event
Market update
Published
15 Jun 2026 23:08
Source
GuruFocus
The Globe and Mail Direct company coverage

Cartesian Therapeutics Announces In Vivo CAR-T Licensing Alliance

Cartesian Therapeutics has formed a strategic licensing alliance with WestGene Biopharma to develop in vivo CAR-T therapies for autoimmune diseases. This collaboration will combine Cartesian’s mRNA payloads with WestGene’s lipid nanoparticle delivery platform, aiming to eliminate

Tone
Neutral 50/100
Event
Market update
Published
13 Jun 2026 12:10
Source
The Globe and Mail
GlobeNewswire Direct company coverage

Cartesian Therapeutics Announces New Employment Inducement Grant

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) announced the granting of an inducement award to a new employee on June 8, 2026. The award includes an option to purchase 6,100 shares of common stock at an exercise price of $5.86, vesting over four years. This grant aligns with Nasdaq

Tone
Neutral 50/100
Event
Market update
Published
13 Jun 2026 09:41
Source
GlobeNewswire
Stock Titan Direct company coverage

New hire at Cartesian gets 6,100 stock options vesting to 2030

Cartesian Therapeutics (NASDAQ: RNAC) has granted a new employee an inducement stock option for 6,100 shares at an exercise price of $5.86. The option vests through June 8, 2030, with 25% vesting after one year and the remainder in monthly installments, and has a ten-year term. T

Tone
Positive 66/100
Event
Market update
Published
12 Jun 2026 20:09
Source
Stock Titan